News

Alnylam has granted Arrowhead a license under its intellectual property that enables the discovery, development, and commercialization of an RNAi therapeutic targeting the hepatitis B virus (HBV).

The company announced the launch of its 2012 global research grant program, open to researchers from academic and non-profit institutions.

This review concentrates on applications of e-nose and e-tongue technology for edible products and pharmaceutical uses.

A new vaccine against the chronic liver disease hepatitis C has shown promising results in a first clinical trial in humans, Oxford University researchers report.

ACH-1625 is a once-daily protease inhibitor with broad genotypic coverage against HCV that was discovered by Achillion and is currently being evaluated in a Phase 2 clinical trial.

Financing to strengthen and diversify Midatech’s product development portfolio.

The molecular diagnostics company is to focus on cancer and cardiology.

The erratic readings were being caused by fretting corrosion at the electrical contact interface of certain metals. Adverse consequences may include inadequate oxygen reaching the tissues in the body (hypoxia), low blood pressure (hypotension), slower than normal heart rate (bradycardia), cardiac arrest, organ damage, acute respiratory distress syndrome (ARDS), neurological deficits, or death.

The Company’s inhibitor against the human cytomegalovirus HCMV, has been granted Orphan Drug Designation in the US for the prevention of HCMV viremia and disease in at risk populations.

The study of half a million pregnant women in the United States found 15.5% of those tested were positive for gestational hypothyroidism, much higher than previously estimated.